JNJ-90106848

JNJ-90106848 is an investigational, orally administered small molecule inhibitor of interleukin-17A (IL-17A), currently being developed by Janssen (a subsidiary of Johnson & Johnson). IL-17A is a pro-inflammatory cytokine that plays a central role in the pathogenesis of various autoimmune and inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting IL-17A, JNJ-90106848 aims to provide an oral alternative to existing injectable biologic therapies that target the IL-17 pathway. The drug is currently in early-stage clinical development, with ongoing studies evaluating its safety, tolerability, and efficacy in healthy volunteers and patients with moderate to severe plaque psoriasis.